Shalanda A Bynum1, Stephanie A S Staras2, Teri L Malo3, Anna R Giuliano4, Elizabeth Shenkman2, Susan T Vadaparampil5. 1. Department of Preventive Medicine and Biometrics, Uniformed Services University of the Health Sciences, Bethesda, Maryland. 2. Department of Health Outcomes and Policy, College of Medicine; and the Institute for Child Health Policy, University of Florida, Gainesville, Florida. 3. Health Outcomes and Behavior Program, Moffitt Cancer Center, Tampa, Florida. 4. Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida; Center for Infection Research in Cancer, Moffitt Cancer Center, Tampa, Florida; Department of Oncologic Science, College of Medicine, University of South Florida, Tampa, Florida. 5. Health Outcomes and Behavior Program, Moffitt Cancer Center, Tampa, Florida; Center for Infection Research in Cancer, Moffitt Cancer Center, Tampa, Florida; Department of Oncologic Science, College of Medicine, University of South Florida, Tampa, Florida. Electronic address: Susan.Vadaparampil@moffitt.org.
Abstract
PURPOSE: Human papillomavirus (HPV) vaccination in the United States remains a public health challenge with vaccine rates of 50%. Although health care providers can facilitate HPV vaccination, several factors may impede their ability to universally recommend the vaccine. To maximize the potential of HPV vaccines, it is important to understand challenges providers face in the clinical environment. The study sought to identify factors associated with recommendation of the HPV vaccine for low-income adolescents in the early (9-10), target (11-12), early adolescent catch-up (13-14), and late adolescent catch-up (15-17) vaccination groups. METHODS: Surveys were mailed between October 2009 and April 2010 to a random sample of Florida-based physicians serving Medicaid-enrolled adolescents. Data were analyzed in 2013. RESULTS: Among early adolescents, discomfort discussing sexually transmitted infections (STIs) with teens (odds ratio [OR] = 1.75), difficulty ensuring vaccine completion (OR = .73), and discomfort discussing STIs with parents (OR = .44) were associated with recommendation. For target adolescents, discomfort discussing STIs with teens (OR = 2.45), time constraints (OR = .70), vaccine efficacy concerns (OR = .65), discomfort discussing STIs with parents (OR = .33), obstetrics/gynecology (OR = .25) and family medicine (OR = .24) specialty, and non-Hispanic black patient (OR = .15) were associated with recommendation. In early catch-up adolescents, concerns that teens will practice riskier behaviors (OR = .57), discomfort discussing STIs with parents (OR = .47), and family medicine specialty (OR = .20) were associated with recommendation. For late catch-up adolescents, family medicine specialty (OR = .13) was associated with recommendation. CONCLUSIONS: Modifiable factors that impede or influence provider recommendations of HPV vaccines can be addressed through intervention. Overall, findings suggest that efforts should focus on sexuality communication and family medicine specialty.
PURPOSE:Human papillomavirus (HPV) vaccination in the United States remains a public health challenge with vaccine rates of 50%. Although health care providers can facilitate HPV vaccination, several factors may impede their ability to universally recommend the vaccine. To maximize the potential of HPV vaccines, it is important to understand challenges providers face in the clinical environment. The study sought to identify factors associated with recommendation of the HPV vaccine for low-income adolescents in the early (9-10), target (11-12), early adolescent catch-up (13-14), and late adolescent catch-up (15-17) vaccination groups. METHODS: Surveys were mailed between October 2009 and April 2010 to a random sample of Florida-based physicians serving Medicaid-enrolled adolescents. Data were analyzed in 2013. RESULTS: Among early adolescents, discomfort discussing sexually transmitted infections (STIs) with teens (odds ratio [OR] = 1.75), difficulty ensuring vaccine completion (OR = .73), and discomfort discussing STIs with parents (OR = .44) were associated with recommendation. For target adolescents, discomfort discussing STIs with teens (OR = 2.45), time constraints (OR = .70), vaccine efficacy concerns (OR = .65), discomfort discussing STIs with parents (OR = .33), obstetrics/gynecology (OR = .25) and family medicine (OR = .24) specialty, and non-Hispanic black patient (OR = .15) were associated with recommendation. In early catch-up adolescents, concerns that teens will practice riskier behaviors (OR = .57), discomfort discussing STIs with parents (OR = .47), and family medicine specialty (OR = .20) were associated with recommendation. For late catch-up adolescents, family medicine specialty (OR = .13) was associated with recommendation. CONCLUSIONS: Modifiable factors that impede or influence provider recommendations of HPV vaccines can be addressed through intervention. Overall, findings suggest that efforts should focus on sexuality communication and family medicine specialty.
Authors: Tanya L Kowalczyk Mullins; Gregory D Zimet; Susan L Rosenthal; Charlene Morrow; Lili Ding; Marcia Shew; J Dennis Fortenberry; David I Bernstein; Jessica A Kahn Journal: Arch Pediatr Adolesc Med Date: 2012-01
Authors: Noel T Brewer; Sami L Gottlieb; Paul L Reiter; Annie-Laurie McRee; Nicole Liddon; Lauri Markowitz; Jennifer S Smith Journal: Sex Transm Dis Date: 2011-03 Impact factor: 2.830
Authors: Jennifer L Young; Ruth G Bernheim; Jeffrey E Korte; Mark H Stoler; Thomas M Guterbock; Laurel W Rice Journal: J Pediatr Adolesc Gynecol Date: 2011-09-09 Impact factor: 1.814
Authors: Jessica A Kahn; Gregory D Zimet; David I Bernstein; Jeremy M Riedesel; Dongmei Lan; Bin Huang; Susan L Rosenthal Journal: J Adolesc Health Date: 2005-12 Impact factor: 5.012
Authors: Allison G Litton; Renee A Desmond; Janice Gilliland; Warner K Huh; Frank A Franklin Journal: J Pediatr Adolesc Gynecol Date: 2011-03-12 Impact factor: 1.814
Authors: Allan Hildesheim; Rolando Herrero; Sholom Wacholder; Ana C Rodriguez; Diane Solomon; M Concepcion Bratti; John T Schiller; Paula Gonzalez; Gary Dubin; Carolina Porras; Silvia E Jimenez; Douglas R Lowy Journal: JAMA Date: 2007-08-15 Impact factor: 56.272
Authors: Marjan Javanbakht; Shauna Stahlman; Susan Walker; Sami Gottlieb; Lauri Markowitz; Nicole Liddon; Aaron Plant; Sarah Guerry Journal: Vaccine Date: 2012-05-03 Impact factor: 3.641
Authors: Manika Suryadevara; Joshua R Bonville; Rachael M Kline; Colleen Magowan; Elizabeth Domachowske; Donald A Cibula; Joseph B Domachowske Journal: Hum Vaccin Immunother Date: 2016-02-02 Impact factor: 3.452
Authors: Yvonne N Flores; Jorge Salmerón; Beth A Glenn; Cathy M Lang; L Cindy Chang; Roshan Bastani Journal: Int J Public Health Date: 2018-12-01 Impact factor: 3.380
Authors: Parth D Shah; Melissa B Gilkey; Jessica K Pepper; Sami L Gottlieb; Noel T Brewer Journal: Expert Rev Vaccines Date: 2014-01-03 Impact factor: 5.217
Authors: Monica L Kasting; Courtney L Scherr; Karla N Ali; Paige Lake; Teri L Malo; Tracy Johns; Richard G Roetzheim; Gwendolyn P Quinn; Susan T Vadaparampil Journal: Fam Med Date: 2017-10 Impact factor: 1.756
Authors: May Rose Isnec Dela Cruz; Jo Ann Umilani Tsark; John Jiangtian Chen; Cheryl Lynn Albright; Kathryn Lenzner Braun Journal: J Cancer Educ Date: 2017-09 Impact factor: 2.037
Authors: Melissa B Gilkey; Teri L Malo; Parth D Shah; Megan E Hall; Noel T Brewer Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-10-22 Impact factor: 4.254